Abstract
Introduction: Current follow‐up arrangements for breast cancer do not optimally
meet the needs of individual patients. We therefore reviewed the evidence on preferences and patient involvement in decisions about breast cancer follow‐up to explore the potential for personalised care.
Methods: Studies published between 2008 and 2017 were extracted from MEDLINE, PsycINFO and EMBASE. We then identified decision categories related to content and form of follow‐up. Criteria for preference sensitiveness and patient involvement were compiled and applied to determine the extent to which decisions were sensitive to patient preferences and patients were involved.
Results: Forty‐one studies were included in the full‐text analysis. Four decision
categories were identified: “surveillance for recurrent/secondary breast cancer;
consultations for physical and psychosocial effects; recurrence‐risk reduction by
anti‐hormonal treatment; and improving quality of life after breast cancer.” There
was little evidence that physicians treated decisions about anti‐hormonal treatment, menopausal symptoms, and follow‐up consultations as sensitive to patient preferences. Decisions about breast reconstruction were considered as very sensitive to patient preferences, and patients were usually involved.
Conclusion: Patients are currently not involved in all decisions that affect them during follow‐up, indicating a need for improvements. Personalised follow‐up care could improve resource allocation and the value of care for patients.
meet the needs of individual patients. We therefore reviewed the evidence on preferences and patient involvement in decisions about breast cancer follow‐up to explore the potential for personalised care.
Methods: Studies published between 2008 and 2017 were extracted from MEDLINE, PsycINFO and EMBASE. We then identified decision categories related to content and form of follow‐up. Criteria for preference sensitiveness and patient involvement were compiled and applied to determine the extent to which decisions were sensitive to patient preferences and patients were involved.
Results: Forty‐one studies were included in the full‐text analysis. Four decision
categories were identified: “surveillance for recurrent/secondary breast cancer;
consultations for physical and psychosocial effects; recurrence‐risk reduction by
anti‐hormonal treatment; and improving quality of life after breast cancer.” There
was little evidence that physicians treated decisions about anti‐hormonal treatment, menopausal symptoms, and follow‐up consultations as sensitive to patient preferences. Decisions about breast reconstruction were considered as very sensitive to patient preferences, and patients were usually involved.
Conclusion: Patients are currently not involved in all decisions that affect them during follow‐up, indicating a need for improvements. Personalised follow‐up care could improve resource allocation and the value of care for patients.
| Original language | English |
|---|---|
| Article number | e13092 |
| Number of pages | 17 |
| Journal | European journal of cancer care |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 May 2019 |
Keywords
- UT-Hybrid-D
